CURRICULUM VITAE

Purushottam Jha

Home Address:

**-** **** ******

Elmhurst, NY-11373

501-***-**** (cell)

E-mail: ac5mkv@r.postjobfree.com

I came to USA in 2000 to start the PhD program at University of Louisville, KY during which I worked on collagen induced arthritis mouse model and the role of complement system. In 2003, I joined Department of Ophthalmology at University of Louisville, KY as a post doc fellow after the completion of PhD and started working on role of complement in various ocular diseases. In 2006, my group at University of Louisville was moving to University of Arkansas and I was offered an Instructor position. So, I joined UAMS and moved with the group. In 2009, I was promoted to Assistant Professor in the same department/lab. Early 2016, I joined The Feinstein Institute for Medical research, Northwell Health in NY, where I worked on role of neutrophils in sepsis model. Beginning of 2017, I joined Enzo life sciences. Currently I am working part time from home as a scientific editor for oncotarget and am looking for a full time position preferably involving Immunological, in-vivo and in-vitro technology.

My research involved investigation of various inflammatory mechanisms in diseases such as autoimmune uveitis (EAAU animal model), age-related macular degeneration (laser induced CNV model), uveal melanoma (using cell lines), glaucoma (laser induced), microbial keratitis, rheumatoid arthritis (collagen induced arthritis model) and sepsis mouse model. Throughout my research career I have focused on identifying various therapeutic targets for inflammatory disease and drug development using both small molecules (such as recombinant proteins) and large molecules (such as antibodies and antigens) for different inflammatory diseases. I have also worked for several industrial projects that involved testing of various therapeutic agents (small and large molecules) for various disorders using both in vivo and in vitro models. I have worked on many clinical research projects and have worked with human samples (blood, serum, aqueous humor). I have published papers that demonstrate my experience with the use of siRNA, flow cytometry, molecular techniques, microbiological, immunological techniques, cell culture and tissue culture

I have published my work in various journals and presented my work at conferences which show my writing and communication skills along with excellent computer skills. I have been actively involved in office and research administration, teaching students, residents and technicians, making sure that the lab is under compliance (IACUC, IRB, OSHA).

Strengths

• Fermentation technology and enzyme/protein engineering

Bioreactor designing and bioprocess of microbial and mammalian cell culture (small scale to large scale production)

Protein purification and functional analysis

Ocular Immunology

• Complement Biology, innate immunity.

• Inflammatory and Autoimmune disorders (in vivo and in vitro).

• Immunohistochemistry, immunocytochemistry, confocal and fluorescent microscopy.

• Protein screening (Western blot, ELISA, Multiplex analysis etc).

• Excellent written and oral communication.

Residency status: Permanent Resident (Green Card)

Education:

Ph.D in Immunology 2003, Department of Microbiology & Immunology University of

Louisville, School of Medicine Louisville, KY

Dissertation Title: “Vaccinia Virus Complement Control Protein ameliorates Collagen Induced Arthritis: potential implications for therapy of rheumatoid arthritis.” A part of this project was to culture SODK1 cell line that were able to express the VCP gene and over express the protein under special culture condition.

MS in Biotechnology 1997, M.D. University, Rohtak, India

Thesis Title: “Production of Lipase from Humicola lanuginosa and its evaluation in for its use in detergent.

BS Honors in Microbiology 1993, Delhi University, Delhi, India

Employment:

Harvard Risk Management. 02/2018- present

Management of sales agents

Screening and recruiting

Syntactx, world trade center, Tower 4, floor 44, NY

Regulatory writer for CSR for European clients

Regulatory writer for CSR/CIR for European and USA clients

Impact Journal, Oncotarget, Boston, MA. 08/2017-current

Scientific Editor (part time)

Selection of the reviewers for the manuscripts.

Enzo Life Sciences, Farmingdale, NY. 01/2017-05/2017

R&D Scientist

Product development.

The Feinstein Institute for Medical Research, Northwell Health, NY. 04/2016-12/2016

Research Scientist

Role of Neutrophils and Neutrophil Extracellular Traps (NET) in sepsis. In this project I purified murine bone marrow neutrophils and expanded them and treated them to induce NET formation. After induction of NET I used them to treat the sepsis in mouse model of cecal ligation puncture model of sepsis in mouse.

Jones Eye Institute, Department of Ophthalmology, University of Arkansas Medical Sciences, Little Rock, AR 07/2006-4/2014

Assistant Professor

Designing and performing experiments (in vitro and in vivo).

Trained lab personals, help troubleshoot experiments,.

Manuscript and grant writing, IACUC approvals.

Presented work at conferences.

Establishing new in vivo and in vitro models for various ocular diseases.

Worked with melanoma cell lines to investigate the effects of different inhibitory proteins to suppress the growth of the melanoma cell lines. I also received a grant for this study.

Studied the role of complement system in Autoimmune Anterior Uveitis (EAAU), an animal model for human idiopathic anterior uveitis, Choroidal Neovascularization (CNV), an animal model for Age related macular degeneration, uveal melanoma and laser induced Glaucoma model. Experiments heavily involved in-vivo immunizations and iv, ip and ocular injections, Immunohistochemistry and Immunofluorescence.

Jones Eye Institute, Department of Ophthalmology, University of Arkansas Medical Sciences, Little Rock, AR 07/2006-5/2014

Instructor

Designing and performing experiments (in vitro and in vivo).

Trained lab personals, help troubleshoot experiments.

Manuscript writing.

Presented work at conferences.

Studied the role of complement system in Autoimmune Anterior Uveitis (EAAU), an animal model for human idiopathic anterior uveitis. Experiments heavily involved in-vivo immunizations and iv, ip and ocular injections, Immunohistochemistry and Immunofluorescence.

Dept. of Ophthalmology and Visual Sciences, University of Louisville, KY. 09/2003- 12/2005

Post Doc

Role of Complement system in AMD and autoimmune anterior uveitis. Experiments heavily involved in-vivo immunizations and iv, ip and ocular injections, Immunohistochemistry and Immunofluorescence.

Indian Institute of Technology-Delhi, Delhi, India. 04/1998-06/2000

Project Associate

Debittering Fruit Juices using microbial enzymes. Experiments heavily involved fermentation technology, protein purification and enzyme engineering. This project involved identifying a special enzyme called naringinase from microbes that was used for treating the grapefruit juice. I designed a serial stage fomenter (100 ml) for this project which was successful.

Isolation of a lipase from Humicola arigunasa and mass production (1 liter upscaled to 10 liter) of the enzyme for use in detergents to remove lipid stains from fabrics.

Publications:

1. Jha P and Kotwal GJ. Vaccinia Virus Complement control protein: Multi -functional protein and a Wonder Drug. J. Biosci. 2003; 28(3): 265-271.

2. Jha P, Smith SA, Justus DE, and Kotwal GJ. Prolonged retention of vaccinia virus complement control protein following I.P. injection: implications in blocking xenorejection. Transplant. Proc. 2003; 35(8): 3160-3162.

3. Scott MJ, Burch PT, Jha P, Peyton JC, Kotwal GJ and Cheadle WG, Inhibition of complement increases early bacterial clearance after polymicrobial sepsis. Surg. Infect. (Larchmt). 2003; 4(4):317-326.

4. Jha P, Smith SA, Justus DE, and Kotwal GJ. Vaccinia virus complement control protein ameliorates collagen-induced arthritic mice. Ann. N.Y. Acad. Sci. 2005; 1056: 55-68.

5. Bora PS, Sohn JH, Cruz JM, Jha P, Nishihori H, Wang Y, Kaliappan S, Kaplan HJ, and Bora NS. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 2005; 174(1):491-497.

6. Jha P, Sohn, JH, Xu, Q, Nishihori, H, Wang, Y, Nishihori, S, Manickam, B, Kaplan, HJ, Bora, PS, and Bora, NS. Complement System Plays a Critical Role in the Development of Experimental Autoimmune Aterior Uveitis (EAAU). Invest. Ophthalmol. Vis. Sci. 2006; 47 (3): 1030-1038.

7. Jha P, Sohn JH, Xu Q, Wang Y, Kaplan HJ, Bora PS, and Bora NS. Suppression of Complement Regulatory Proteins (CRPs) Exacerbates Experimental Autoimmune Anterior Uveitis (EAAU). J. Immunol. 2006; 176(12): 7221-31.

8. Bora NS, Kalliappan S, Jha P, Xu Q, Sohn JH, Dhaulakhandi DB, Kaplan HJ and Bora PS. Complement Activation via Alternative Pathway Is Critical in the Development of Laser-Induced Choroidal Neovascularization: Role of Factor B and Factor H. J. Immunol. 2006, 177(3):1872-8

9. Jha P, Bora PS, Sohn JH, Kaplan HJ, and Bora NS. Complement system and the eye. Adv. Exp. Med. Biol. 2006; 586:53-62.

10. Sohn JH, Bora PS, Jha P, Kaplan HJ, and Bora NS. Immunosuppressive Intraocular Microenvironments: Complement and Innate Immunity. Chemical Immunology and Allergy, 2007; 92, 105-114.

11. Bora NS, Kaliappan S, Jha P, Xu Q, Sivasankar B, Harris CL, Morgan BP, and Bora PS. CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration. J. Immunol. 2007; 178(3):1783-1790.

12. Jha P, Bora PS, and Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol. Immunol. 2007; 44(16):3901-3908.

13. Jha P, Matta B, Lyzogubov V, Tytarenko R, Bora PS, and Bora NS. Apoptosis in the Resolution of Experimental Autoimmune Anterior Uveitis (EAAU). Invest. Ophthalmol. Vis. Sci. 2007, 48(11):5091-5100.

14. Bora NS, Jha P, Bora PS. The role of complement in ocular pathology. Semin Immunopathol. 2008 Feb 26.

15. Kaliappan S, Jha P, Lyzogubov VV, Tytarenko RG, Bora NS, Bora PS. Alcohol and nicotine consumption exacerbates choroidal neovascularization by modulating the regulation of complement system. FEBS Lett. 2008; 582(23-24): 3451-3458. PMCID: PMC2987649

16. Matta B, Jha P, Bora PS, Bora NS. Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells. Am. J. Pathol. 2008; 173(5):1440-1454. PMCID: PMC2570134

17. Jha P, Manickam B, Matta B, Bora PS, Bora NS. Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis. J. Biol. Chem. 2009; 284(45):314**-*****. PMCID: PMC2781536

18. Matta B, Jha P, Bora PS, Bora NS. 2010. Antigen specific tolerance inhibits autoimmune uveitis in pre-sensitized animals via deletion and CD4+CD25+ T- regulatory cells. Immunol. and Cell Biol. 2010; 88(2):187-196. PMCID: PMC2824791

19. Lyzogubov VV, Tytarenko RG, Jha P, Liu J, Bora NS and BoraPS. Role of Ocular Complement Factor H in Murine Model of Choroidal Neovascularization. Am. J. Pathol. 2010; 177(4):1870-1880. PMCID: PMC2947282

20. Jha P, Bora PS and Bora NS. Role of complement in ocular immune response. In: Encyclopedia of Eye (Editors: Dart DA, Besharse JC, and Dana R). 2010, Vol. 4, pp 160-164.

21. Manickam B, Jha P, Hepburn NJ, Morgan BP, Harris CL, Bora PS and Bora NS. Suppression of Complement Activation by Recombinant Crry Inhibits Experimental Autoimmune Anterior Uveitis (EAAU). Mol. Immunol. 2010; 48(1-3): 231-239. PMCID: PMC2993852

22. Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, Tytarenko RG, Fraser DH, Morgan BP and Bora PS. Recombinant Membrane Targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice. J Biol Chem. 285 (44): 338**-*****, 2010. PMID: 20736175

23. Uwaydat S., Jha P, Tytarenko R, Brown H, Wiggins M, Bora PS, Bora NS. The use of topical honey in the treatment of corneal abrasions and endotoxin induced keratitis in an animal model. Curr. Eye Res. 2011 Aug 3. PMID: 21812661.

24. Liu J, Jha P, Lyzogubov VV, Tytarenko RG, Bora NS, Bora PS. Relationship between Complement Membrane Attack Complex, Chemokine (C-C Motif) Ligand 2 (CCL2) and Vascular Endothelial Growth Factor in Mouse Model of Laser-induced Choroidal Neovascularization. J. Biol. Chem. 2011, 286(23):209**-*****.

25. Manickam B, Jha P, Matta B, Bora PS and Bora NS. Inhibition of Complement Alternative Pathway Suppresses Experimental Autoimmune Anterior Uveitis (EAAU) by Modulating T Cell Responses. J of Biol Chem. 2011; 286: 8472-8480.

26. Jha P, Banda H, Tytarenko R, Bora PS, Bora NS. Complement mediated apoptosis leads to the loss of retinal ganglion cells in animal model of glaucoma. Mol. Immunol. 2011; 48(15-16):2151-2158. PMID: 21821293.

27. Bora NS, Jha P, Lyzogubov VV, and Bora PS. Emerging role of complement in ocular diseases. Current Immunology Reviews. 2011; 7: 360-367.

28. Lyzogubov V, Wu X, Jha P, Tytarenko R, Triebwasser M, Kolar G, Bertram P, Bora PS, Atkinson JP, Bora NS. Complement regulatory protein CD46 protects against choroidal neovascularization in mice.

Abstracts:

1. Jha P and Chand S, Production and Application of Microbial Enzyme for Citrus Fruit Juice debittering, Poster presentation in second national Students Symposium on Biochemical Engineering & Biotechnology at IIT Delhi (February 2000).

2. Jha P, Smith SA, Justus DE, and Kotwal GJ. Vaccinia virus complement control protein ameliorates collagen-induced arthritis in mice. Oral Presentation in IX European Meeting on Human Disease held in Trieste Italy (September 2003) Abstract published in Molecular Immunology (Eds. Daha MR & Melief CJM) 2003, Sept 40 (2-4): 181.

3. N.S. Bora, H. Nishihori, J.H. Sohn, S. Nishihori, P.Jha, H.J. Kaplan, P.S. Bora. Complement System in Experimental Autoimmune Anterior Uveitis. ARVO 2004 (Invest. Ophthalmol. Vis. Sci. 2004 45: E-Abstract 540).

4. Q. Xu, P. Jha, J.-H. Sohn, H.J. Kaplan, P.S. Bora, N.S. Bora. Local and Systemic Complement Activation in Experimental Autoimmune Anterior Uveitis. ARVO 2005 (Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 996).

5. P. Jha, Qin Xu, J.-H. Sohn, H. Nishihori, S. Nishihori, Y. Wang, H.J. Kaplan, P.S. Bora, N.S. Bora. Complement System in Immunopathogenesis of Experimental Autoimmune Anterior Uveitis. ARVO 2005 (Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 978).

6. Q. Xu, P. Jha, J.-H. Sohn, H.J. Kaplan, P.S. Bora, N.S. Bora. Complement Activation and complement receptor proteins in Experimental Autoimmune Anterior Uveitis. ARVO 2006 (Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 4533).

7. B. Manickam, P. Jha, Qin Xu, J.-H. Sohn, P.S. Bora and N.S. Bora. Expression of C3a and C5a Receptors During Experimental Autoimmune Anterior Uveitis (EAAU). ARVO 2006 (Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 4534)

8. P. Jha, Qin Xu, J.-H. Sohn, Wang, H.J. Kaplan, P.S. Bora, N.S. Bora. Suppression of Complement Regulatory Proteins (CRPs) Exacerbates Experimental Autoimmune Anterior Uveitis (EAAU). ARVO 2006 (Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 2916).

9. P.S. Bora, S.Kaliappan, P.Jha, J.-H. Sohn, Q. Xu, D. Dhaulakhandi, H. Kaplan, N.Bora. Complement Activation by Alternative Pathway is Critical in the Development of Laser-Induced Choroidal Neovascularization. ARVO 2006 (Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 4167).

10. J.-H.Sohn, E.Bodek, P.Jha, Y.Wang, P.Bora, H.Kaplan, N.Bora. Complement Regulatory Proteins Are Important for the Survival of Human Retinoblastoma. ARVO 2006 (Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 5161).

11. P. Jha, B. Matta, D. Nounamo, P.S. Bora, and N.S. Bora. Role of Complement Regulatory Proteins (CRPs) and Apoptosis in the Resolution of Experimental Autoimmune Anterior Uveitis (EAAU). ARVO-Asia 2007, Singapore.

12. P.S. Bora, S. Kaliappan, P. Jha, B. Sivasankar, C.L. Harris, B.P. Morgan, and N.S. Bora. Role of Complement Regulatory Protein, CD59, in the Development of Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration. ARVO 2007 (Invest. Ophthalmol. Vis. Sci. 2007 48: E-Abstract 1769).

13. P. Jha, B. Matta, D. Nounamo, P.S. Bora, and N.S. Bora. Both Extrinsic and Intrinsic Pathways of Apoptosis are involved in the Resolution of Experimental Autoimmune Anterior Uveitis (EAAU). ARVO 2007 (Invest. Ophthalmol. Vis. Sci. 2007 48: E-Abstract 2645).

14. B. Matta, P. Jha, P.S. Bora and N.S. Bora Intravenous Administration of Melanin Associated Antigen Inhibits Experimental Autoimmune Anterior Uveitis (EAAU). ARVO 2007 (Invest. Ophthalmol. Vis. Sci. 2007 48: E-Abstract 5210).

15. B. Manickam, P.Jha, P.S. Bora and N.S. Bora. Suppression of Experimental Autoimmune Anterior Uveitis by recombinant Soluble Complement Regulatory Protein. ARVO, 2007 (Invest. Ophthalmol. Vis. Sci. 2007 48: E-Abstract 2646).

16. B. Matta, P. Jha, P. S. Bora, and N. S. Bora. CD4+CD25+t Regulatory Cells Play a Critical Role in Induction of Tolerance Against EAAU. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 2513).

17. P. Jha, B. Matta, D. Nounamo, J. Sauer, P. S. Bora, and N. S. Bora. Role of Complement Factor H (CFH) in Immune Evasion of Uveal Melanoma Cells. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 2396).

18. J.-H. Sohn, P. Jha, P. S. Bora, and N. S. Bora. Role of Complement in Corneal Inflammation. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 2386).

19. P. S. Bora, S. Kaliappan, P. Jha, and N. S. Bora. Therapeutic Potential of Recombinant Membrane-Targeted Form of MAC Regulator CD59 in Laser-Induced CNV. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 293).

20. S. Kaliappan, P. Jha, V. V. Lyzogubov, R. G. Tytarenko, N. S. Bora, and P. S. Bora. Increased Severity of Choroidal Neovascularization in Laser Treated Rats after Alcohol and Nicotine Feeding. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 5171).

21. S. H. Uwaydat, M. N. Wiggins, P. Jha, H. H. Brown, and N. S. Bora. Topical Honey for the Treatment of Corneal Abrasions. ARVO, 2008 (Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 3406).

22. B. Matta, P. Jha, P. S. Bora, and N. S. Bora. Inhibition of Experimental Autoimmune Anterior Uveitis (EAAU) by Immune Tolerance to Uveitogenic Antigen in Sensitized Animals. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 829.

23. V. V. Lyzogubov, R. G. Tytarenko, P. Jha, P. S. Bora, and N. S. Bora. Suppression of Complement Factor H Increases Deposition of Membrane Attack Complex and Vessel Growth in Mouse Model of CNV. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 3752.

24. J. Liu, P. Jha, P. S. Bora, and N. S. Bora. Expression Profile of MAC, Chemokines and Angiogenic Growth Factors in Laser-Induced Choroidal Neovascularization (CNV). Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 3754.

25. B. Manickam, P. Jha, P. S. Bora, and N. S. Bora. Auto-Antigen Localized to Rat Eye Induces Experimental Autoimmune Anterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 2632.

26. P. Jha, B. Matta, R. Tytarenko, P. S. Bora, and N. S. Bora. Complement Activation in Chronic Ocular Hypertension Model. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 2649.

27. A. E. Buckner, C. Ekworomadu, P. Jha, P. Bora, and N. Bora. Crucial Role of Complement Component C3 in Herpes Stromal Keratitis. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 2390.

28. B. Matta, P. Jha, P. S. Bora, and N. S. Bora. Role of T Effector and CD4+CD25+FoxP3+ T Regulatory Cells in Idiopathic Anterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 4843.

29. R. G. Tytarenko, V. V. Lyzogubov, P. Jha, J. Liu, N. S. Bora, and P. S. Bora. Role of Ocular Complement Factor H in Animal Model of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 6188.

30. . J. Liu, P. Jha, V. V. Lyzogubov, P. S. Bora, and N. S. Bora. Recombinant Membrane-Targeted CD59 Inhibits the Growth of Choroidal Neovascular Complex in Murine Model of Laser-Induced Choroidal Neovascularization (CNV). Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 405.

31. P. Jha, B. Matta, R. G. Tytarenko, P. S. Bora, and N. S. Bora. Role of Complement in the Protection of Retinal Ganglion Cells in Chronic Ocular Hypertension Model of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 3188.

32. V. V. Lyzogubov, R. G. Tytarenko, P. Jha, X. Wu, G. Kolar, J. P. Atkinson, P. S. Bora, N. S. Bora. Role Of CD46 In Laser Induced Choroidal Neovascularization. ARVO Annual Meeting. May 1-5, 2011, Fort Lauderdale, Florida.

33. J. Liu, P. Jha, V. V. Lyzogubov, R. G. Tytarenko, P. S. Bora, N. S. Bora Relationship between Complement, Chemokine and Angiogenic Growth Factor in Laser-induced Choroidal Neovascularization (CNV). ARVO Annual Meeting. May 1-5, 2011, Fort Lauderdale, Florida.

34. B. Matta, B. Manickam, P. Jha, J. Liu, P.S. Bora, N.S. Bora. Inhibition of Complement Alternative Pathway Suppresses Experimental Autoimmune Anterior Uveitis (EAAU) by Modulating T Cell Responses. ARVO Annual Meeting. May 1-5, 2011, Fort Lauderdale, Florida.

35. P. Jha, R.G. Tytarenko, H. Banda, B. Matta, P.S. Bora, N.S. Bora. Complement Mediated Apoptosis Leads to the Loss of Retinal Ganglion Cells in Animal Model of Glaucoma. ARVO Annual Meeting. May 1-5, 2011, Fort Lauderdale, Florida.

36. B. Matta, P. Jha, P.S. Bora, N.S. Bora. Role of iC3b-CR3 interaction in Experimental Autoimmune Anterior Uveitis. 2012, Fort Lauderdale, Florida.

37. V. V. Lyzogubov, P. Jha, R. G. Tytarenko, N. S. Bora, P. S. Bora. Complement Activation and Changes in RPE and Retina after Subretinal Treatment of Polyethylene Glycol (PEG) in Mice. 2012, Fort Lauderdale, Florida.

38. P. Jha, V. V. Lyzogubov, P.S. Bora, N.S. Bora. Membrane Attack Complex Induces Apoptosis In Retinal Ganglion Cells In Chronic Ocular Hypertension Model. 2012, Fort Lauderdale, Florida.

Skills and Techniques:

Molecular

PCR, RT- PCR, RNA isolation, cDNA synthesis, primer designing, siRNA designing, in vivo and in vitro antisense/siRNA gene silencing, plasmid purification, gene cloning (viral vectors).

Biochemical

Cell fractionation, preparation of detergent soluble/insoluble membranes, enzyme assays, western blots, ELISA, SDS-PAGE, 2-D gel electrophoresis, protein phosphorylation assays, Transfection of mammalian cells, immunohistochemical/cytochemical protein analysis, microscopy (light, fluorescence, and immunofluorescence, confocal), cell proliferation assays, apoptosis assays and adenoviral vector preparation and delivery techniques.

Immunological

Flow cytometry, Complement assays (classical and alternative), Immunofluorescence, immunohistochemistry, complement inhibition assays, purification of complement components, T-cell proliferation assay, nucleated cell cytotoxicity assay, macrophage and dendritic cell culture.

Cell culture / Microbiological techniques

Propagation and culture of cell lines, primary cells microbes, transfection of cell lines, standard aseptic tissue culture practices, culturing and freezing of cell lines and microbes,

small scale and large scale fermentation, protein and enzyme purification from microbial culture, isolation of mononuclear cells from peripheral blood by density gradient centrifugation (ficoll and percoll); peritoneal macrophages from mouse and rats by lavage; T cell purification by nylon wool column, viral vector transfections.

Animal Models

Collagen-induced arthritis (mice and rats); Adjuvant-induced arthritis (rats); Experimental autoimmune anterior uveitis (EAAU in rats); Endotoxin-induced uveitis (mice); Endotoxin-induced keratitis (rats); Cornea injury model (rats), Glaucoma (rats and mice), Laser-induced choroidal neovascularization (mice and rats).

Compliance, safety and Regulation

Followed Occupational Health and safety guideline and other required guidelines throughout and trained others to do so.

Contact this candidate